Tocilizumab for the Treatment of Behcet's Syndrome

Status Terminated

Clinical Trial Summary

This is a double-blind placebo controlled study targeting individuals with active Behcet's Syndrome who have oral ulcers and are resistant (have not responded after 4 weeks) to conventional treatments. Maximum allowable dose of colchicine (0.6mg twice a day) and stable dose for 4 weeks before enrollment. Prednisone or equivalent (< 10mg/day) permitted if dose stable for 6 weeks prior to enrollment.

The study will investigate the safety of tocilizumab for this vasculitic condition in addition to its efficacy.

The planned sample size is 30 participants per arm for a total of 60 participants. The study would be for 3 months, with a safety follow up at 2 months after study termination.

Study participants will stay on their current treatments and either tocilizumab or placebo infusions will be given every 4 weeks in addition. Patients will be randomized to Actemra IV 8mg/kg Q 4 weeks X 3 doses or placebo.

Clinical Trial Description

Behcet's syndrome is a vasculitis that causes oral and genital ulcerations, skin lesions, eye disease and arthritis, in addition to vascular complications with thrombophlebitis, thrombosis and rarely central nervous system involvement. IL-6 activity has been suggested in the pathogenesis in some studies. Tocilizumab with its unique mode of action among biologic agents may be a good candidate in this orphan disease. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01693653
Study type	Interventional
Source	New York University School of Medicine
Contact
Status	Terminated
Phase	Phase 2
Start date	September 2012
Completion date	November 2013

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03274648` - Dietary Interventions and Butyrate Production in Behçet's Patients	N/A
Completed	`NCT04961463` - Evaluation of the Psychoeducation Program Given to Behcet's Patients in the Context of the Roy Adaptation Model	N/A
Completed	`NCT05142995` - Sleep Related Breathing Disorders, Anxiety, Depression and Quality of Life Assessment in Behcet's Disease
Recruiting	`NCT00931957` - Etanercept: Single Blind Control Study in Ocular Manifestations of Behcet's Disease	N/A
Completed	`NCT03514056` - Frequency of Fibromyalgia in Behcet Disease
Not yet recruiting	`NCT03771768` - Diode Laser Versus Topical Corticosteroids in Management of Oral Ulcers in Behcet's Disease	N/A
Terminated	`NCT03554161` - Tocilizumab for the Treatment of Refractory Behcet's Uveitis	Phase 2
Recruiting	`NCT04738864` - Neuro-ultrasound Assessment in Behcet's Disease	N/A
Completed	`NCT03264391` - Evaluation of Macular Vascular Changes in Behcet's Disease Using Optical Coherence Tomography Angiography
Completed	`NCT04386824` - Erectile Dysfunction in Patients With Non Ocular Behçet's Disease
Completed	`NCT03962335` - Gut Microbiota and Behcet's Syndrome: a Dietary Intervention Trial (MAMBA Study)	N/A
Completed	`NCT01532570` - Clinical Study of TA-650 in Patients With Behcet's Disease (BD) With Special Lesions	Phase 3
Not yet recruiting	`NCT04186559` - Topical Pentoxifylline Gel on Behcet's Disease Genital Ulcers	Phase 2
Terminated	`NCT04218565` - Golimumab for the Treatment of Refractory Behcet's Uveitis	Phase 2
Not yet recruiting	`NCT03747354` - Assessment of Disease Activity in Behcet by Complete Blood Count	N/A
Recruiting	`NCT05200715` - AutoInflammatory Disease Alliance Registry (AIDA)
Completed	`NCT05098678` - Zinc Supplementation and Behçet's Syndrome	N/A
Completed	`NCT00866359` - A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Behçet Disease	Phase 2
Completed	`NCT00483184` - Low Dose Interferon Alpha Treatment for Oral Ulcers of Behcet's Disease	Phase 2
Completed	`NCT05032248` - Uses of Tacrolimus in Behcet Disease	N/A